TNGX

NASD Tango Therapeutics, Inc.
Oct 7, 2026 · 6:22 PM ET LAST TRADE Market Closed

$21.83 ↑ +0.00 (+0.00%) Trading Up from the previous close of $21.83, $0.63 below the day’s high of $22.46

YTD change
+146.39%
vs 20-day SMA
-8.35%
vs 200-day SMA
+3.51%

Price ranges

Previous day
$21.36 $23.16
open $23.16 close $21.90
-$1.26 (-5.44%)
Today
$21.38 $22.46
open $21.64 now $21.83
+$0.19 (+0.88%)
Past week
$21.36 $25.43
from $24.42 now $21.83
-$2.59 (-10.61%)
Past month
$21.36 $25.92
from $22.70 now $21.83
-$0.87 (-3.83%)
This year
$8.66 $34.39
from $8.86 now $21.83
+$12.97 (+146.39%)

Price & Performance

+2.10 (+10.61%) / 6M

$18.59$23.71$28.84$33.96Apr 7Jul 8Oct 6

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 36.5% away from all-time highs of $34.39
  • TNGX is up 146% since the beginning of the year
  • TNGX is up 199% over the past 12 months
  • TNGX is down 4% over the past 1 month
  • 25% of all TNGX investors are betting against TNGX

TNGX reads not so good: price sits above one of the two key moving averages, the 12-month move is +200.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.37
Earnings momentum -4.6% Quarterly EPS growth
Quarterly change -4.6%

Valuation

P/E ratio N/A
Enterprise value $2.3B
Beta 1.12

Balance sheet & scale

IncomeN/A
Revenue$53.8M
Cash$1.0B
Debt$32.0K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $3.7B

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, Antoni Ribas and Barbara Weber in 2017 and is headquartered in Boston, MA.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $738.72 +1.69%
IQV IQVIA Holdings Inc $259.98 -2.30%
CRL Charles River Laboratories International, Inc. $304.96 -1.87%
ICLR ICON Plc $161.69 -3.94%
IT Gartner, Inc. $184.92 -1.51%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.